|
Mexico Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Mexico Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Mexico .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Mexican pharmaceutical and healthcare industry.
Competitive intelligence, Mexican pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Mexican market.
The Mexico Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Mexico Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Mexican pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Mexico to test other views – a key input for successful budgeting and strategic business planning in the Mexican pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Mexican Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Mexico .
- Exploit The Latest Competitive Mexican Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Mexico .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Mexico Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Mexico Pharmaceuticals And Healthcare Industry SWOT |
| Mexico Political SWOT |
| Mexico Economic SWOT |
| Mexico Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Americas Pharmaceutical Business Environment Rankings For Q209 |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Mexico – Market Summary |
| Regulatory Regime |
| Intellectual Property Environment |
| Table: Mexican Marketing Applications In Alleged Violation Of Patent Rights |
| Counterfeit Drugs |
| Pricing And Reimbursement Issues |
| Other Regulatory Developments |
Chapter - Industry Developments |
| Epidemiology |
| Table: Mortality Rates In Mexico Per 100,000 Population, 2003-2005 |
| Healthcare Sector |
| Health Insurance |
| Medical Tourism |
| Pharmaceutical Sector |
| Generic Drug Sector |
| Multinational Activity |
| Recent Pharmaceutical Company Activity |
| Research And Development Sector |
| Table: Clinical Studies In Mexico By Therapeutic Area, 2004 |
| Retail And Distribution Sector |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Drug Market Forecast, 2003-2013 |
| Industry Forecasts |
| Table: Health Expenditure Forecast, 2003-2013 |
| Macroeconomic Forecasts |
| Table: Mexico – Economic Activity |
| Prescription Market Forecast |
| Table: Prescription Drug Market Forecast, 2003-2013 (US$mn unless otherwise stated) |
| OTC Drug Market Forecast |
| Table: OTC Drug Market Forecast, 2003-2013 (MNXmn unless otherwise stated) |
| Generic Drug Market Forecast |
| Table: Generic Drug Market, 2003-2013 |
| Patented Drug Market Forecast |
| Table: Patented Drug Market, 2003-2013 |
| Medical Device Market Forecast |
| Table: Mexico's Medical Devices, 2006-2013 (US$mn unless otherwise stated) |
| Pharmaceutical Export/Import Forecasts |
| Table: Pharmaceutical Trade Indicators, 2003-2013 (US$mn) |
| Other Healthcare Data |
| Table: Healthcare Sector Data And Forecasts, 2003-2013 |
| Key Risks To BMI's Forecast Scenario |
Chapter - Company Profiles |
| Multinational Companies |
| Pfizer |
| GlaxoSmithKline (GSK) |
| Sanofi-Aventis |
| Eli Lilly |
| Bristol-Myers Squibb (BMS) |
| Novartis Farmacéutica |
| Bayer |
| Boehringer Ingelheim Promeco |
| Merck KGaA |
| Roche |
| Indigenous Manufacturer Profile |
| Liomont |
| Strides Latina (Solara) |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Mexico Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
For this Q209 update of Mexico’s Pharmaceutical and Healthcare report, we have updated our forecast extending through to 2013. Over the next five years, we expect total drug market spending to increase from US$13.48bn in 2008 to US$27.33bn by 2013, representing a compound annual growth rate (CAGR) of 15.2%. We believe the main drivers for growth include the increasing disease burden from heart disease and diabetes, which will result in long-term spending on prescription medicines. Additionally, the expansion of the health insurance schemes operating in the country has led to more patients seeking doctor consultations and treatment. We expect overall healthcare spending to increase from US$64.9bn in 2008 to US$100.8bn by 2013, with a CAGR of 9.2%.
During February 2009, the National Institute of Public Health (INSP) announced that the pricing regulations imposed on medicines do not account for per capita income. It also alluded to irregularities in other pricing policies that favour higher drug prices. BMI believes that the government must address the discrepancies in drug prices, which will negatively affect spending in the sector and indirectly lead to the increased use of counterfeit medicines.
The Mexican government is trying to expand access to healthcare; however, BMI expects that total drug expenditure will be negatively affected in remote and low income regions, further impeding government efforts in this area. The INSP revealed that, although most patients are covered by a public or private health insurance plan, they are still purchasing medicines out-of-pocket from private and not public pharmacies. According to the World Health Organisation (WHO), 93% of all private health spending was through cash payments in 2006.
Mexican health authorities are increasing public awareness of preventable heart disease by updating general practitioners (GPs) on the long-term implications of these illnesses on the population and healthcare system. The College of Internal Medicine in Mexico (CMIMA) has outlined that a stronger focus on ‘primary prevention’ will gradually reduce incidences of avoidable heart disease.
The Mexican Ministry of Health has increased the budget for the Seguro Popular health insurance programme by just under a third (31%) for 2009. BMI believes this move was to maintain the government’s target of ensuring that the entire population is covered by 2010. The US$3.63bn boost is expected to provide an extra 11.1mn families with health insurance. The health ministry has been successful in securing greater participation in the scheme, with 7.3mn families enrolled during 2007, a 43% increase from the previous year. A key feature of the wide participation has been the means-tested basis for the insurance, exempting those on very low incomes from payment. By the end of 2008, health insurance providers Seguro Popular, Mexican Institute of Social Security (IMSS), and the Social Services Institute for Public Employees (ISSSTE) covered 82mn people in Mexico.
|
Mexico Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |